Citigroup
HTGM

Citigroup’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Citigroup’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,719
Closed -$21K – 6596
2022
Q2 		$21K Buy
1,719
+1,469
+588% +$13.8K ﹤0.01% 4992
2022
Q1 		$4K Buy
+250
New +$8.02K ﹤0.01% 5932
2016
Q2 		– Hold
0
– – – 7560
2016
Q1 		– Hold
0
– – – 7877
2015
Q4 		– Sell
-1
Closed -$1K – 7962
2015
Q3 		$1K Buy
+1
New +$1.54K ﹤0.01% 7250

Other funds holding HTGM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup's HTGM Position: Q3 2022 in Review

Citigroup sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2022, closing a stake of 1,719 shares — an estimated $21K sold.

Citigroup first reported a position in HTGM in Q3 2015 and held it in 3 quarters. The position peaked at $21K in Q2 2022. 18 funds tracked by Wall St. Rank hold HTGM as of Q3 2022.

  • Citigroup reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 1,719 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2022, an estimated $21K.
  • Citigroup first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2015 and held it in 3 quarters.
  • Citigroup's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $21K in Q2 2022.
  • 18 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.